Lisata Therapeutics Announces Participation in Upcoming Conferences in May
April 27 2023 - 9:00AM
Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the
“Company”), a clinical-stage pharmaceutical company developing
innovative therapies for the treatment of advanced solid tumors and
other serious diseases, today announced that David J. Mazzo, PhD,
Chief Executive Officer of Lisata, will present at three upcoming
conferences. Details of the events are as follows:
LSX World CongressMay 3-4, 2023 |
London, United Kingdom
Dr. Mazzo will deliver a live presentation on
Wednesday, May 3, 2023, at 11:15 a.m. British Summer time / 6:15
a.m. Eastern time. Management will also participate in one-on-one
meetings with investors throughout the conference. For more
information about the LSX World Congress, please visit
https://www.lsxleaders.com/lsx-world-congress.
Sidoti Micro-Cap Conference May
10-11, 2023 | Virtual
Dr. Mazzo will deliver a virtual presentation on
Wednesday, May 10, 2023, at 10:00 a.m. Eastern time. Management
will also participate in virtual one-on-one meetings with investors
throughout the conference. For more information about the Sidoti
Micro-Cap Virtual Conference, please visit
https://www.sidoti.com/events.
Bio€quity Europe 2023May 14-16,
2023 | Dublin, Ireland
Dr. Mazzo will deliver a live presentation on
Monday, May 15, 2023, at 1:41 p.m. Irish Standard time / 8:41 a.m.
Eastern time. Management will also participate in one-on-one
meetings with investors throughout the conference. For more
information about Bio€quity Europe 2023, please visit
https://conferences.biocentury.com/bioequity-europe.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage
pharmaceutical company dedicated to the discovery, development, and
commercialization of innovative therapies for the treatment of
advanced solid tumors and other major diseases. Lisata’s lead
product candidate, LSTA1, is an investigational drug designed to
activate a novel uptake pathway that allows co-administered or
tethered anti-cancer drugs to target and penetrate solid tumors
more effectively. LSTA1 actuates this active transport system in a
tumor-specific manner, resulting in systemically co-administered
anti-cancer drugs more efficiently penetrating and accumulating in
the tumor, while normal tissues are not affected. LSTA1 also has
the potential to modify the tumor microenvironment, with the
objective of making tumors more susceptible to immunotherapies.
LSTA1 has demonstrated favorable safety, tolerability, and activity
in clinical trials to enhance delivery of standard-of-care
chemotherapy for pancreatic cancer. Lisata and its collaborators
have also amassed significant non-clinical data demonstrating
enhanced delivery of a range of existing and emerging anti-cancer
therapies, including chemotherapeutics, immunotherapies and
RNA-based therapeutics. Lisata is exploring the potential of LSTA1
to enable a variety of treatment modalities to treat a range of
solid tumors more effectively. For more information on the Company,
please visit www.lisata.com.
Contact:
Investors and Media:Lisata Therapeutics, Inc.John
MendittoVice President, Investor Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lisata Therapeutics (NASDAQ:LSTA)
Historical Stock Chart
From Jul 2023 to Jul 2024